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Abstract
Introduction. It has been suggested that the metastatic potential of neoplastic cells can be predicted on the basis 
of their biological features, including expression of proteins involved in the epithelial to mesenchymal transi-
tion (EMT). Therefore, the purpose of this work was to (1) evaluate the expression of EMT markers: ZEB2, 
vimentin, N-cadherin, TWIST, PTEN, survivin, E-cadherin, Ki-67 and GLUT-1, (2) assess mutation status of 
two genes: PIK3CA and KRAS, and (3) investigate the potential relationships between the studied biomarkers 
and clinicopathological factors in clear-cell renal cell carcinoma (ccRCC). 
Material and methods. Tumor tissue samples (embedded in paraffin blocks) from 159 patients undergoing rad-
ical nephrectomy were analyzed. Proteins expression was evaluated immunohistochemically. DNA mutations 
were analyzed on DNA isolated from tumor tissue and amplified by real-time PCR detection using suitable 
fluorescent labeled TaqMan assays. 
Results. One hundred and seven men and 52 women of mean age of 63.1years were enrolled. Fifty four cancers 
at pTNM stage I–II and 98 at pTNM III–IV stage were diagnosed. There were 30 Fuhrman grade G1, 61 Fuhrman 
G2, 49 Fuhrman G3 and 19 Fuhrman G4 tumors. A negative correlation between ZEB2 (p = 0.047, r = –0.172) or 
E-cadherin expression (p = 0.027, r = –0.191) and TNM was observed. Positive association between grade and 
Ki-67 (p < 0.001), survivin (p < 0.001), vimentin (p < 0.001) immunoreactivity and negative association between 
TWIST expression (p = 0.029) or PTEN expression (p = 0.013) were found. Ki-67 expression was positively 
correlated with survivin (p < 0.001, r = 0.617), vimentin (p = 0.001, r = 0.251) and N-cadherin (p = 0,009, r = 0.207) 
immunoreactivity which can suggest tumor aggressiveness. TWIST was negatively correlated with E-cadherin 
(p < 0.001, r = –0.284), vimentin (p < 0.001, r = –0.297) and N-cadherin (p < 0.002, r = –0.241). ZEB2 was 
not associated with ccRCC grade but was negatively correlated with E-cadherin (p = 0.055, r= –0.153) and 
PTEN (p = 0.006). GLUT-1 expression was inversely linked to E-cadherin expression (p = 0.022, r= –0.182). 
Mutations in PIK3CA and KRAS genes were not found in any of the studied ccRCC tumors. 
Conclusions. Low-grade tumors showed higher expression of ZEB2 and TWIST proteins than high-grade tumors, 
which can suggest that EMT in ccRCC begins at early stages of tumor development and, therefore, evaluation of 
these proteins, together with other biomarkers, may be useful for assessment of the tumor metastatic potential. 
(Folia Histochemica et Cytobiologica 2018, Vol. 56, No. 4, 195–206)
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Introduction
Clear-cell renal cell carcinoma (ccRCC) has the 
highest incidence and accounts for 70% to 80% of 
all histological types of renal cell cancers (RCCs) [1]. 
This is a heterogeneous disease and its natural course 
is still unpredictable, i.e. the prognosis of patients 
at a similar stage of locally advanced ccRCC varies 
widely. Morbidity and mortality in advanced ccRCC 
is high. Up to a quarter of patients display distant 
metastases or advanced regional disease at the time 
of presentation and diagnosis [2]. 
In many tumors, biological markers can identify 
prognostic subgroups for individual treatment; how-
ever, at present, clinical use of biomarkers to predict 
outcome in RCC is not validated [3] and urine bio-
markers as well as liquid biopsy analysis of circulating 
tumor DNA remain the area of active investigation 
[4]. The prognosis of patients with localized ccRCC 
and tumor metastatic potential cannot be accurately 
predicted by standard variables such as clinicopatho-
logical characteristics. Therefore, after surgical treat-
ment of advanced cancer and the occurrence of single 
metastatic focus, the physician is facing the problem 
of choosing the right therapy — surgery/radiation 
or systemic treatment. It has been shown that the 
limited/high metastatic potential can be predicted 
on the basis of biological features of tumor cells: 
expression of proteins involved in the transformation 
from epithelial to mesenchymal phenotype [5, 6] or 
genetic mutations responsible for acquisition of the 
ability to metastasize of cancer cells [7]. Some of 
them become a therapeutic target for the treatment 
of RCC. PTEN (phosphatase and tensin homolog 
detected on chromosome 10) is a tumor suppressor 
gene involved in the homeostatic maintenance of the 
phosphatidylinositol 3 kinase (PI3K)/AKT cascade [8]. 
Inactivation of PTEN causes elevated AKT activation. 
The most important gene mutations for the devel-
opment and progression of metastatic disease are: 
PIK3CA — playing a role in tumor cell invasion, and 
KRAS — an oncogene involved in signal transduction 
in hypoxia-inducible pathway activated by epidermal 
growth factor receptor (EGFR), which become targets 
for drug intervention in RCC [1, 6, 9].
Epithelial-mesenchymal transition (EMT) is 
related to proliferation, invasion and metastasis of 
tumor [5, 9, 10]. Increased cell proliferation can be 
detected by the assessment of expression of the Ki-67 
antigen, which is present during all active phases of 
the cell cycle. EMT is typified by a common spectrum 
of changes in cell morphology, gene expression, and 
signaling pathways, which can confer resistance to 
therapy [10–12]. During EMT many cancer cells lose 
epithelial cell features and acquire mesenchymal cell 
features including repression of E-cadherin and over-
expression of N-cadherin, and cytoskeletal protein 
— vimentin [10–12]. Transcriptional downregulation 
of E-cadherin appears to be an important event in 
the progression of various epithelial tumors [11, 13]. 
However, recently, it has been shown on a mouse 
model that rather than being a binary process, EMT 
develops from epithelial to completely mesenchymal 
states through an intermediate state [14]. Hypoxia 
and EMT have been identified as key events in tumor 
invasion and metastasis [15]. Stabilization of hypox-
ia-inducible factor 1a (HIF-1a) (constantly expressed 
in RCC [16]) has been shown to control, directly or 
indirectly, the expression of EMT-related transcrip-
tion factors, array of genes that encode proteins 
essential for cancer cell functioning  under hypoxic 
conditions, such as ZEB2 (zinc finger E-box-binding 
homeobox also known as Smad interacting protein-1 
(SIP1)) that shows specific DNA binding activity to 
the E-cadherin promoter and inhibits E-cadherin 
transcription [10, 17], TWIST [10, 18] and glucose 
transporter 1 (GLUT-1) [19]. 
It has been found that hypoxia promotes EMT in 
vitro by regulating TWIST/E-cadherin pathway [11]. 
Recent studies have demonstrated that TWIST is re-
markably upregulated in a large number of malignant 
tumors, plays a crucial role in the onset of metastatic 
behavior by promoting cell migration and motility 
[20], and inhibits apoptosis [21]. Tumor hypoxia may 
contribute to the conversion of differentiated tumor 
cells into cancer stem cells [22]. This may be corre-
lated with overexpression of survivin, a protein that 
inhibits apoptosis, regulates cell division and enhances 
angiogenesis [23]. In ccRCC it has been shown that 
overexpression of survivin leads to high metastatic 
capacity of cells and poor patients’ outcome [24]. 
EMT and markers of recurrence in ccRCC have 
not yet been established [6]. Therefore, the purpose of 
the study was to: (1) evaluate the expression of mes-
enchymal cell markers: ZEB2, vimentin, N-cadherin, 
TWIST, and survivin, E-cadherin, PTEN, Ki-67, and 
GLUT-1 (2) assess mutations in two genes: PIK3CA 
(p.E542K and p.H1047R) and KRAS (p.G12D and 
p.G13D) and (3) investigate the potential relation-
ships between the expression of biomarkers and 
clinical-pathological variables as well as the possibility 
to predict metastatic potential of ccRCC.
Material and methods
Patients and samples. The study protocol was approved 
by the local Ethical Committee at the Regional Medical 
Chamber in Cracow. All procedures performed in the study 
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involving human participants were in accordance with the 
ethical standards of the institutional and/or national research 
committee and with the 1964 Declaration of Helsinki and 
its later amendments or comparable ethical standards. In-
formed consent was obtained from all individuals included 
in the study.
Between November 2013 and January 2016, a group of 
159 patients with locally advanced ccRCC (clinical stage 
I–IV) were included into the study in which a tumor biopsy 
was taken during curative surgery. 
Tumors were classified according to the WHO clas-
sification of renal neoplasms [25], clinical (cTNM) and 
pathological (pTNM) stages according to the AJCC TNM 
2010 classification [26] as well as Fuhrman grade [27] were 
assessed. 
Immunohistochemical analysis and scoring. Protein ex-
pression was evaluated immunohistochemically on histolog-
ical specimens using a suitable antibody and BrightVision 
visualization system (Bright Vision detection system, cat. 
no. DPVB-110HRP, Immunologic, Duiven, Netherlands). 
Following rehydration, and antigen retrieval (TRS — Target 
Retrieval Solution (10 ×), cat. No. S1699, DakoCytomation 
Denmark A/S, Glostrup, Denmark) 5 µm sections were 
incubated with proper antibody according to the procedure 
given in Table 1. Next, the sections were stained with diam-
inobenzidine (DAB — Peroxidase substrate KIT, cat.no. 
SK-4100, Vector Laboratorie, Inc., Burlingame, CA, USA), 
counterstained with hematoxylin, dehydrated and mounted. 
Negative control slides (omitting the primary antibody) and 
positive controls (with known protein expression) were in-
cluded in each staining run. Additionally, for GLUT-1 red 
blood cells, and for PTEN, ZEB2 stromal and inflammatory 
cells served as internal positive control. Immunoreactivity 
was scored as the number of positive tumor cells over total 
(500–1000) tumor cells — labeling index (LI): several (5–7) 
microscopic fields of each tumor tissue sections were exam-
ined. PTEN protein expression was considered positive when 
> 30% of tumor cells exhibited nuclear staining and ZEB2 
was assessed at the invasive front (hot spot) of the tumors. 
Slides were evaluated by two investigators unaware of the 
clinicopathological variables. 
Table 1. Procedures for immunohistochemical reactions
Antigen Antibody Clone Manufacturer Antigen retrieval Dilution Incubation
Ki-67 Mouse monoclonal MIB-1 DAKOCytomation
Denmark A/S
Cat. No. M7240, Glostrup, 
Denmark
TRS (Tris Retrieval 
Solution), (pH = 6.0), 
water bath, 96o C,  
50 min
1 : 100 4oC overnight
E-cadherin Mouse monoclonal NCH-38 DAKOCytomation
Denmark A/S
Cat. No. M3612, Glostrup, 
Denmark
TRS, (pH = 6.0),  
water bath, 96o C,  
40 min
1 : 50 4oC overnight
N-cadherin Mouse monoclonal 6G11 DAKOCytomation
Denmark A/S
Cat. No. M3613, Glostrup, 
Denmark
TRS, (pH = 6.0),  
water bath,
96o C, 40 min
1 : 75 4oC overnight
PTEN Rabbit monoclonal D4.3 Cell Signaling
Cat. No. 9188
Danvers, MA, USA
TRS, (pH = 6.0),  
water bath,
96o C, 50 min
1 : 50 37oC 
60 min
TWIST Rabbit polyclonal Ab-cam
Cat. No. Ab49254
Cambridge, MA, USA
TRS, (pH = 6.0),  
water bath, 96o C,  
50 min
1 : 75 4oC overnight
Vimentin Mouse
monoclonal V9
Bio Genex
Cat. No. MU074-UC
Fremont, CA, USA
none 1 : 200 4oC overnight
Survivin Mouse monoclonal EP2880 Bio Genex
Cat. No.  NU503-UC,
Fremont, CA, USA
TRS, (pH = 6.0),  
water bath,
96o C, 40 min
1 : 30 4oC overnight
ZEB2 Rabbit
polyclonal
Sigma-Aldrich
Cat. No. HPA003456, St. 
Louis, MO, USA
TRS, (pH = 6.0),  
water bath,
96o C, 40 min
1 : 300 4oC overnight
GLUT-1 Rabbit
polyclonal
EMD Millipore
Corporation
Cat.No. 07-1401
Temecula, CA, USA
TRS, (pH = 6.0),  
water bath, 96o C,  
40 min
1 : 200 4oC overnight
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qPCR analysis of KRAS and PIK3CA mutation status. DNA 
was isolated from 5 µm thick formalin-fixed, paraffin-embed-
ded tumor tissue sections. ReliaPrep FFPE gDNAMiniprep 
System (Promega Corp Madison, WI, USA) was used for 
DNA extraction according to the manufacturer’s protocol. 
qPCR reactions were performed using ViiA 7 Real-Time 
PCR System (Applied Biosystems, Foster City, CA, USA).
Two mutations in KRAS and two in PIK3CA genes were 
analyzed in each patient. 
For establishing PIK3CA mutation status, three different 
assays on the same plate were run: (i) PIK3CA 775 TaqMan® 
Mutation Detection Assay (Assay ID Hs00000831_mu) 
to detect H1047R mutation, (ii) PIK3CA 760 TaqMan® 
Mutation Detection Assay (Assay ID Hs00000822_mu) 
for E542K mutation, (iii) PIK3CA TaqMan Mutation 
Detection Reference Assay (Assay ID Hs00001025_rf) to 
detect conservative fragment of PIK3CA gene which serves 
as quality control of isolated DNA. Similarly, to establish 
KRAS mutation status, three different assays on the same 
plate were run: (i) KRAS 521 TaqMan® Mutation Detection 
Assay (Assay ID Hs00000121_mu) for G12D mutation de-
tection, (ii) KRAS 532 TaqMan® Mutation Detection Assay 
(Assay ID Hs00000131_mu) for G13D mutation, (iii) KRAS 
TaqMan Mutation Detection Reference Assay (Assay ID 
Hs00000174_rf) to detect conservative fragment of KRAS 
gene. All TaqMan Mutation Detection Assays were supplied 
by Applied Biosystems. 
The final volume of qPCR reaction was 20 µl per well. 
Each well contained the following reagents: 2 µl of proper 
TaqMan® Mutation Detection Assays, 4 µl (20 ng) of 
isolated DNA, 10 µl of TaqMan Genotyping Master Mix 
(Applied Biosystems), 0.4 µl of Exogenous IPC Template 
DNA (internal positive control), 2 µl of Exogenous IPC 
Mix (Applied Biosystems) and 1.6 µl of nuclease-free water 
suitable for PCR (Ambion, Austin, TX, USA). The following 
thermocycling conditions were applied: initial denaturation 
— 95°C, 10 minutes; 5 cycles: 92°C, 15 seconds, 58°C for 
1 minute; 40 cycles: 92°C for 15 seconds, 60°C for 1 minute. 
Data obtained from qPCR reactions were analyzed using 
Mutation Detector Software to determine the presence or 
absence of mutations.
Statistical analysis. Statistical analysis was performed 
with STATISTICA v. 12 (Statsoft, Krakow, Poland). For 
determination of mean values of variables and standard 
errors of means (SE) the descriptive statistics were used. 
Intergroup differences in the mean values were tested with 
one-way ANOVA test (grade) or Student’s t-test. Asso-
ciations between investigated categorical parameters and 
clinicopathological variables were evaluated by Pearson’s 
Chi2 test. The relationship between proteins expression 
(continuous variables) was tested with Pearson correlation 
and between proteins expression and TNM and pTNM (cat-
egorical variables) using Spearman correlation. Differences 
were considered significant at p value of < 0.05.
Results
Demographic and clinicopathological  
characteristics of the ccRCC patients
The analyzed group of ccRCC patients consisted of 
107 men and 52 women of median age of 64.0 (30–85) 
years which did not differ between male and female 
patients (Table 2). The patients’ clinicopathological 
characteristics are listed in Table 2. The majority (104) 
of patients were diagnosed with cTNM stage 1–2 and 
pTNM stage 3–4 (98) and there was no statistically 
significant difference in stage between both sexes 
(Table 2). In five (3.1%) patients cTNM and in seven 
(4.4 %) patients pTNM was not assessed (nephron 
sparing surgery). Ninety one patients had low-grade 
tumors (30 cases — G1, according to the Fuhrman sys-
tem, and 61 G2, while 68 patients — high grade tumors 
(49 G3 and 19 G4 cases). This variables differed (p = 
= 0.031) between male and female subgroups (Table 2). 
Relationship between clinicopathological  
variables and proteins expression 
The immunoreactivity of the studied proteins was as-
sessed in all tumors. In Figure 1, nuclear positivity for 
Ki-67 (Fig. 1A), survivin (Fig. 1B), PTEN (Fig. 1F), 
TWIST (Fig. 1G), ZEB2 (Fig. 1I), membranous 
for E-cadherin (Fig. 1C), N-cadherin (Fig. 1D), 
Table 2. Gender-related clinicopathological characteristics 
of ccRCC patients
Variable N Sex p value*
Women Men
Age (years)
mean ± SD
159 63.4 ± 10.4
(N = 52)
62.9 ± 9.5
(N = 107)
0.768
cTNM (N = 154)
1
2
3
4
74
30
18
32
28
10
4
8
46
20
14
24
0.447
pTNM (N = 152)
1
2
3
4
48
6
73
25
19
2
18
9
29
4
55
16
0.351
G (according to Fuhrman) (N = 159)
1
2
3
4
30
61
49
19
15
21
9
7
15
40
40
12
0.031
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Figure 1. Immunoreactivity of the studied proteins in the tumor tissue of 159 ccRCC patients. Nuclear immunopositivity of: 
(A) Ki-67 (grade [G] 2, male patient; (B) survivin (G4, male patient); (F) PTEN (G2, male patient); (G) TWIST (G3, male 
patient); (I) ZEB2 (G1, female patient). Membranous staining of: (C) E-cadherin (G1, female patient); (D) N-cadherin 
(G3, male patient). Membranous/cytoplasmic expression of (E) GLUT-1 (G3, male patient), and cytoplasmic staining of (H) 
vimentin (G4, male patient) in primary ccRCC. The slides were stained by immunohistochemistry as described in Methods. 
Scale bars = 20 µm. 
A B C
D E F
G H I
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membranous/cytoplasmic for GLUT-1 (Fig. 1E) and 
cytoplasmic for vimentin (Fig. 1H) are presented. 
The mean labeling index values for each protein 
and the correlation between proteins expression and 
TNM and pTNM are presented in Table 3. With the 
increase of clinical tumor stage (cTNM) expression 
of E-cadherin (p = 0.027, r = –0.167) and ZEB2 
(p = 0.046, r = –0.207) significantly decreased. Weak 
positive correlations between pTNM and expression 
of survivin (p = 0.028, r = 0.178) and weak negative 
association with E-cadherin (p = 0.038, r = –0.186) 
and ZEB2 (p = 0.031, r = –0.175) were observed. 
However, there was a statistically significant increase 
in the rate of tumor cell proliferation (Ki-67 LI, p < 
< 0.001), expression of survivin (p < 0.001), vimentin 
(p < 0.001), decrease of TWIST expression (p = 0.029) 
and percentage of PTEN- positive tumors (p = 0.013) 
with tumor grade (Fig. 2). Grade 4 tumors showed 
the highest immunoreactivity for Ki-67, survivin and 
vimentin, and the lowest expression of TWIST and 
PTEN (Fig. 2). A statistically significant relationship 
between tumor grade and biomarker expression has 
not been demonstrated for GLUT-1 (p = 0.344), 
E-cadherin (p = 0.354), N-cadherin (p = 0.648) and 
ZEB2 (p = 0.216). 
Correlation between immunoexpression  
of the studied proteins
Analysis of the correlation between protein expres-
sions showed that the expression of vimentin (p = 
= 0.001, r = 0.252), N-cadherin (p = 0.009, r = 0.207) 
and survivin (p < 0.001, r = 0.617) was positively cor-
related with Ki-67. TWIST expression was negatively 
correlated with the expression of vimentin (p < 0.001, 
r = –0.297), E-cadherin (p < 0.001, r = –0.284) and 
N-cadherin (p = 0.002, r = –0.241). Survivin was 
positively associated with vimentin (p < 0.001, r = 
= 0.345) whereas GLUT-1 showed negative correla-
tion with E-cadherin (p = 0.022, r = –0.182). ZEB2 
was inversely linked to E-cadherin (p = 0.055, r = 
= –0.153) and PTEN (p = 0.006).
Gene mutations
None of the patients showed any mutations in the 
PI3KCA and KRAS genes in ccRCC tumor tissue.
Discussion
We studied expressions of proteins known to be in-
volved in the EMT process, and PI3KCA and KRAS 
genes mutations in order to assess their association 
with clinicopathological variables in ccRCC. The 
results of our study might indicate that the ability of 
ccRCC to undergo EMT may not be directly associ-
ated with histological grade, suggesting the need for 
biological markers assessment. We have shown the 
change from epithelial to mesenchymal phenotype 
based on higher expression of vimentin, N-cadherin, 
Ki-67, survivin and also repression of E-cadherin and 
PTEN which may demonstrate an increased potential 
for metastasis. ZEB2 was inversely linked to E-cad-
herin and PTEN which suggests its role in the EMT 
process. However, ZEB2 and TWIST expression was 
negatively associated with tumor grade. Additionally, 
TWIST expression was negatively correlated with the 
expression of vimentin, E-cadherin and N-cadher-
in. This may indicate two functions of the TWIST 
protein, depending on the tumor grade: (i) higher 
expression of this protein in differentiated tumors 
may be indicative of the acquisition of tumor stem 
cell traits by neoplastic cells, which promotes tumor 
growth, and (ii) negative correlation with E-cadherin 
Table 3. The association between protein expression and clinicopathological variables in ccRCC patients
Variable Labeling index (%) x ± SE
TNM Ki-67 Survivin E-cadherin GLUT-1 Vimentin TWIST N-cadherin ZEB2 PTEN1
1 22.9 ± 1.4 5.4 ± 0.6 34.7 ± 2.62 62.8 ± 2.7 42.8 ± 2.7 25.7 ± 1.8 59.8 ± 3.3 20.8 ± 1.43 50.0
2 24.5 ± 2.2 5.4 ± 1.1 27.4 ± 4.4 66.1 ±  3.6 37.4± 3.7 24.5 ± 3.0 53.8 ±5.0 16.9 ± 2.0 33.3
3 25.6 ± 2.8 7.3 ± 1.7 22.5 ± 3.7 73.8 ± 5.5 43.3 ± 5.7 27.2 ± 4.5 60.4 ± 7.8 20.6 ± 3.0 26.7
4 26.0 ± 2.3 7.8 ± 1.1 26.6 ± 3.3 66.2 ± 4.0 38.7 ± 4.8 24.4 ± 3.9 60.0 ± 4.3 13.8 ± 2.6 26.9
pTNM
1 22.1 ± 1.5 4.8 ± 0.54 35.8 ± 3.35 60.3 ± 3.5 43.1 ± 3.2 26.8 ± 2.3 59.0 ± 4.1 21.3 ± 1.5 53.7
2 20.0 ± 3.1 3.3 ± 1.1 31.0 ± 10.4 65.5 ±3.0 35.0 ± 9.1 26.3 ± 7.1 51.0 ± 7.0 16.5 ± 3.4 16.7
3 25.5 ± 1.3 6.6 ± 0.7 27.9 ± 2.4 69.8 ± 2.3 39.2 ± 2.8 23.0 ± 1.9 58.6 ± 3.3 17.7 ± 1.6 34.7
4 27.7 ± 2.7 9.0 ± 1.4 22.2 ± 3.8 63.7 ± 5.4 43.6 ± 5.9 28.2 ± 4.6 56.4 ± 5.3 15.7 ± 2.8 36.4
1percentage of PTEN positive tumors, 2p = 0.078, 3p = 0.044, 4p = 0.014, 5p = 0.064. Statistically significant differences were analyzed by one-way ANOVA test.
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may be indicative of EMT induction. Both functions 
are important in the EMT process. We showed high 
expression of GLUT-1, even in well differentiated 
tumors, and its negative correlation with E-cadherin 
proves that hypoxia favors the EMT process, what 
may support general statement [10, 15]. In our study, 
values of mean labeling index of the analyzed proteins 
are within the ranges found in renal cell carcinomas 
[19, 24, 28–37]. However, it is difficult to compare the 
results because the authors often did not provide raw 
data but the information on cut-off value for positive 
or negative expression important for patients’ survival. 
Furthermore, they analyzed not only ccRCC but all 
histological types of RCC [29–32, 34–35], and also 
often used tissue microarrays (0.6 mm tissue blocks) 
with much lower number of cells counted (risk of 
exclusion of defective cores) [19]. 
In our study there was no relationship between 
cTNM or pTNM and proteins’ expression, apart from 
E-cadherin and ZEB2, where significant decrease 
Figure 2. Relationships between histological grade of ccRCC (Fuhrman scale) and immunoexpression of Ki-67 (A), Sur-
vivin (B), Vimentin (C), TWIST (D) and PTEN (E). One-way ANOVA test (A–D) and Pearson’s Chi2 test (E) were used to 
analyses the differences. Symbols represent mean values ± SE.
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in expression levels was observed with cTNM which 
supports the earlier published study [30]. However, 
there was a statistically significant increase in the rate 
of tumor cell proliferation (Ki-67 LI), expression of 
survivin, vimentin, and a decrease in the percentage 
of PTEN- positive tumors with grade which is in 
agreement with other authors’ results [28, 29, 31, 35]. 
The expression of GLUT-1, ZEB2, E-cadherin and 
N-cadherin was not associated with histological grade 
of ccRCC. In our material high hypoxia (GLUT-1 LI 
> 60%) was found even in differentiated tumors, and 
well-differentiated tumors showed higher expression 
of ZEB2 and TWIST proteins than high-grade tum-
ors, which can suggest that EMT in ccRCC began 
early in tumor development. 
It was reported that malignant carcinoma cells are 
characterized by the loss of both cell-cell adhesion and 
cellular differentiation, which correlate with E-cad-
herin downregulation [10]. During the EMT process 
epithelial cadherin (E-cadherin) is downregulated, 
while neural cadherin (N-cadherin) is upregulated, 
a phenomenon referred to as ‘cadherin switch’ that 
occurs in cancer cells of mesenchymal phenotype [10]. 
The results of our study suggests that downregulation 
of E-cadherin was not completed since the expression 
of E-cadherin did not decrease and expression of 
N-cadherin did not increase significantly with pTNM 
and tumor grade as shown in another study of renal 
cell carcinomas [30]. Furthermore, the expression of 
these proteins was positively correlated. This may 
imply the association between phenotypic plasticity 
of carcinoma cells and their metastatic potential 
and may be in agreement with study of Armstrong 
et al. [36] showing that circulating tumor cells from 
metastatic solid tumors (prostate and breast cancers) 
co-express E-cadherin and N-cadherin. Recently, it 
has been also shown that breast carcinoma cells with 
hybrid epithelial and mesenchymal phenotypes are 
more capable of entering the circulation and forming 
metastases [14].
In our study the expression of E-cadherin, even 
in low-grade tumors, was relatively low (mean 30%) 
in comparison to other cancer types [37, 38]. This 
may be connected with (1) expression of TWIST and 
ZEB2, repressors of E-cadherin, the expression of 
which was higher in low-grade tumors. Therefore, in 
ccRCC, the switch from E-cadherin to N-cadherin 
does not seem to promote EMT as in other tumor 
types [39]. Low expression of E-cadherin might also 
be caused by (2) hypermethylation of E-cadherin 
[10] or (3) controlling EMT by miR-200 family which 
targets E-cadherin repressor — ZEB2 [40, 41]. In our 
study, the immunoexpression of ZEB2 was inversely 
linked to E-cadherin immunoexpression which is in 
accordance with the results of other studies [17, 34]. 
In breast tumor cell lines it has been shown that ZEB2 
may directly activate/upregulate genes typical for mes-
enchymal cells (such as vimentin) and cell migration 
[42]. However, we did not demonstrate correlation 
between ZEB2 and vimentin, although other authors 
[34] showed positive correlation between expressions 
of these proteins (they analyzed not only ccRCC but 
all histological types of RCC). Therefore, it seems that 
clinicopathological significance of ZEB2 expression 
is unclear or may be not important in mesenchymal 
transition of ccRCC cells (not fully expressed mesen-
chymal phenotype) that affects only a small fraction 
of the tumor cell population at any given time [13] or 
may show a transient process occurring during EMT 
[14]. In our study, vimentin expression was associat-
ed with increasing tumor grade. Other authors [33] 
observed significant increase in vimentin expression 
also with clinical stage which we cannot confirm. Our 
results have shown that hypoxia is high (mean GLUT-
1 LI > 60%) even in differentiated ccRCC tumors, 
which may point to the inducible role of hypoxia in 
RCC etiology suggested by other authors [16, 43, 44]. 
This indicates that malignant progression is based on 
dynamic processes which cannot be explained solely 
by irreversible genetic alterations, but must be addi-
tionally regulated by the tumor environment. In our 
study, GLUT-1 expression was not associated with tu-
mor stage and grade which was also reported by other 
authors [19, 32]. We found a weak negative correlation 
between GLUT-1 and E-cadherin expression which 
can suggest that more hypoxic areas favor EMT and 
repression of E-cadherin [10] and prove that these 
processes are linked in the pathogenesis of ccRCC. 
Hypoxia is necessary for the induction of HIF-1, 
which has been described to induce tumor cell 
dedifferentiation towards an immature phenotype 
and similarly to maintain tumor cells with stem-cell 
properties [22]. HIF-1 induces genes encoding glyc-
olytic enzymes and proteins that facilitate transport 
of glucose into cells. Similarly to other authors [6, 10, 
44] we found negative correlation between GLUT-1 
and E-cadherin immunoexpressions. 
We reported that ZEB2 was negatively correlated 
not only with E-cadherin but also with PTEN. This 
may be in agreement with the study of Milella et al.[8] 
who showed that PTEN regulates a broad spectrum of 
biological functions, modulating the flow of informa-
tion from membrane-bound growth factor receptors 
to nuclear transcription factors, in concert with other 
tumor supressors and oncogenic signaling pathways. 
In our study, expression of PTEN decreased with tu-
mor grade, which suggests loss of inhibitory role of this 
protein on the PI3K/AKT/mTOR signaling pathway, 
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suggested by other authors [45]. However, we did not 
find mutations in PIK3CA and KRAS genes. Maybe it 
is because PIK3CA mutations are rare in ccRCC and 
are present only in 2–5% of tumors [46] or result from 
intratumoral molecular heterogeneity which should be 
studied by novel sampling strategies [47]. Similarly to 
other authors [47–50] we also did not detect mutations 
in KRAS gene. It seems that mutations in PIK3CA and 
KRAS are not significant events in the development 
of ccRCC. Lack of mutation in the PIK3CA gene re-
sponsible for the synthesis of the catalytic subunit of 
the phosphoinositide-3-kinase (PI3K) the key enzyme 
of this pathway, may be the cause of tumor resistance 
to everolimus — an inhibitor of the mTOR pathway. 
The finding of the absence of mutation in the KRAS 
gene in all studied patients, may help in qualification 
of patients for targeted treatment (lack of mutation 
in the KRAS gene may indicate tumor sensitivity to 
inhibitors of signal transduction for growth factors).
Expression of mesenchymal proteins (vimentin, 
N-cadherin) was positively correlated with Ki-67 and 
survivin immunoexpression which was found also in 
another study [33] and indicates a higher potential for 
metastasis, because it was shown that survivin inhibits 
apoptosis and promotes cell proliferation [23].
In our study, TWIST expression was negatively 
associated with tumor grade, repression of vimen-
tin, E-cadherin, and N-cadherin immunoreactivity. 
TWIST is known as the driver of EMT and is needed 
for tumor initiation and maintenance [20, 51]. It was 
shown that increase in the level of this protein during 
the EMT process is sufficient to suppress the death of 
cells initiated by a proapoptotic signal such as lack of 
cell adhesion [21]. Therefore, it has been suggested 
that TWIST can promote not only tumor invasion and 
metastasis but also is necessary for conferring can-
cer stem cell properties through EMT-independent 
mechanism [20, 52]. EMT and stem cell competence 
could be decisive for malignant tumor progression 
by allowing such tumor cells to detach, migrate and 
disseminate in the body and subsequently to form new 
colonies at the metastatic site [53]. 
In our study, TWIST was negatively correlated 
with E-cadherin, which confirms other authors` 
studies [17, 51]. TWIST expression was negatively 
associated with grade, contrarily to the results of 
Ohba and colleagues who analyzed 156 RCC includ-
ing papillary and chromophobe tumors [54]. There 
may be two reasons for this discrepancy: (1) the 
authors considered nuclear and cytoplasmic staining 
of TWIST positivity, while we counted only nuclear 
expression, according to the data sheet from the man-
ufacturer, because it was demonstrated that TWIST 
undergoes nuclear translocation under the effect of 
mechanotransduction (matrix stiffness) to induce 
EMT [55]; (2) it has been reported recently, that only 
cytoplasmic expression of TWIST was associated with 
higher tumor grade, and a significant difference be-
tween the nuclear expression of TWIST in different 
RCC subtypes was observed [56].
We have shown that TWIST expression was also 
negatively correlated with the expression of vimentin, 
N-cadherin and E-cadherin. This may indicate two 
functions of the TWIST protein, depending on the 
tumor grade. (1) Higher expression of this protein in 
differentiated tumors may be indicative of the acqui-
sition of tumor stem cell traits by tumor cells, what is 
in agreement with the study of Friberg et al. [2], who 
had shown that even small RCCs have the capacity 
to generate metastases. (2) Negative correlation with 
E-cadherin may be indicative of EMT induction. Both 
functions are important in the EMT process. 
If the transition or partial transition from epithe-
lial to mesenchymal phenotype is molecularly linked 
to a dedifferentiation program, this could indicate 
that certain mesenchymal properties are related to 
a stemness phenotype. For example, TWIST expres-
sion in low-grade tumors has a role in inhibiting ter-
minal differentiation by interfering with the ARF-p53 
tumor suppressor pathway and apoptosis [21]. Beck 
and colleagues [20] showed that different levels of 
TWIST1 in mouse skin SCC regulate tumor initiation, 
stemness, and progression, but independently of its 
EMT function. Similarly as in our study, TWIST was 
expressed at early stages of skin tumorigenesis [20]. 
Also a direct link between the EMT, TWIST and 
stem-cell properties was described at the molecular 
level  in mammary epithelial cells [57].
The EMT program and cancer stemness are 
mechanistically linked [52]. The EMT program pre-
dominantly operates during tumor metastasis, while 
cancer stem cell properties are also needed for tumor 
initiation.  Therefore, it is unclear whether these 
two properties are independent or cooperate during 
different stages of tumor progression or represent an 
intermediate state between epithelial and mesenchy-
mal phenotype [14].
Conclusions
The results of our study suggest that the ability of 
ccRCC to undergo EMT may not be directly linked to 
tumor malignancy. The change in epithelial-to-mes-
enchymal transition, based on higher expression of 
vimentin, N-cadherin, Ki-67, survivin and E-cadherin 
and PTEN repression may indicate an increased po-
tential for metastasis. Although ZEB2 and TWIST 
were inversely linked to E-cadherin they were neg-
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atively associated with ccRCC grade which suggests 
an early beginning of EMT program in ccRCC de-
velopment, and points to the need for the biological 
markers assessment. The predictive value of all the 
biological markers will be revealed only after analysis 
of the correlation between biomarkers expression and 
clinical outcomes (relapse and metastasis, overall and 
progression free survival).
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